X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-03-18 | ARVN | Arvinas, Inc. | Berkowitz Noah | Chief Medical Officer | S - Sale | $8.59 | -8,658 | 110,023 | -7% | -$74,372 | ||||||
| M | 2025-03-14 | VREO | Vireo Growth Inc. | Chicago Atlantic Credit Opportunities, LLC | 10% | P - Purchase | $0.38 | +123,022 | 110,676,205 | 0% | +$46,800 | |||||
| D | 2025-03-17 | MIRM | Mirum Pharmaceuticals, Inc. | Howe Jolanda | SVP, GLOBAL CONTROLLER | S - Sale+OE | $44.35 | -57,606 | 4,841 | -92% | -$2,554,763 | |||||
| D | 2025-03-17 | MIRM | Mirum Pharmaceuticals, Inc. | Radovich Peter | Pres, COO | S - Sale+OE | $44.21 | -7,879 | 18,672 | -30% | -$348,364 | |||||
| D | 2025-03-17 | MIRM | Mirum Pharmaceuticals, Inc. | Peetz Christopher | CEO | S - Sale+OE | $44.21 | -27,279 | 347,211 | -7% | -$1,206,122 | |||||
| D | 2025-03-14 | RYTM | Rhythm Pharmaceuticals, Inc. | Mazabraud Yann | EVP, Head of International | S - Sale+OE | $51.48 | -75,000 | 40,370 | -65% | -$3,861,272 | |||||
2025-03-14 | LYEL | Lyell Immunopharma, Inc. | Klausner Richard | Dir | P - Purchase | $0.60 | +158,000 | 3,811,199 | +4% | +$94,942 | ||||||
| A | 2025-03-11 | COLL | Collegium Pharmaceutical, Inc | Dreyer Scott | EVP, Chief Commercial Officer | S - Sale | $30.00 | -15,387 | 126,676 | -11% | -$461,672 | |||||
2025-03-18 | ALZN | Alzamend Neuro, Inc. | Ault Milton C III | Dir, 10% | P - Purchase | $0.96 | +5,000 | 199,222 | +3% | +$4,810 | ||||||
2025-03-14 | IGMS | Igm Biosciences, Inc. | Weber Steven | Principal Accounting Officer | S - Sale | $1.23 | -1,701 | 28,881 | -6% | -$2,092 | ||||||
2025-03-14 | IGMS | Igm Biosciences, Inc. | Tahir Misbah | CFO | S - Sale | $1.23 | -7,329 | 180,324 | -4% | -$9,015 | ||||||
| D | 2025-03-17 | CYRX | Cryoport, Inc. | Zecchini Edward J | Chief Digital, Tech Officer | S - Sale+OE | $6.29 | -1,140 | 66,911 | -2% | -$7,173 | |||||
2025-03-14 | IGMS | Igm Biosciences, Inc. | Harler Mary Beth | CEO | S - Sale | $1.23 | -7,329 | 339,703 | -2% | -$9,015 | ||||||
| D | 2025-03-17 | CYRX | Cryoport, Inc. | Stefanovich Robert | CFO | S - Sale+OE | $6.29 | -1,659 | 191,419 | -1% | -$10,438 | |||||
2025-03-14 | IGMS | Igm Biosciences, Inc. | Decker Lisa Lynn | Chief Business Officer | S - Sale | $1.23 | -4,512 | 73,529 | -6% | -$5,550 | ||||||
| D | 2025-03-17 | CYRX | Cryoport, Inc. | Sawicki Mark W | Chief Scientific Officer | S - Sale+OE | $6.29 | -2,092 | 85,436 | -2% | -$13,162 | |||||
| D | 2025-03-17 | CYRX | Cryoport, Inc. | Shelton Jerrell | Pres, CEO | S - Sale+OE | $6.29 | -4,620 | 765,399 | -1% | -$29,068 | |||||
2025-03-17 | LYEL | Lyell Immunopharma, Inc. | Newton Charles W. | CFO | P - Purchase | $0.56 | +200,000 | 372,725 | +116% | +$111,620 | ||||||
2025-03-14 | LYEL | Lyell Immunopharma, Inc. | Seely Lynn | Pres, CEO | P - Purchase | $0.61 | +175,000 | 712,500 | +33% | +$106,190 | ||||||
| D | 2025-03-17 | VRCA | Verrica Pharmaceuticals Inc. | Hayes Christopher G. | GC | S - Sale+OE | $0.65 | -4,315 | 176,458 | -2% | -$2,805 | |||||
| D | 2025-03-14 | BCAX | Bicara Therapeutics Inc. | Meisner Lara | GC | S - Sale+OE | $12.90 | -79,146 | 0 | -100% | -$1,021,211 | |||||
2025-03-14 | COLL | Collegium Pharmaceutical, Inc | Tupper Colleen | EVP, CFO | S - Sale | $30.00 | -977 | 164,269 | -1% | -$29,313 | ||||||
2025-03-14 | COLL | Collegium Pharmaceutical, Inc | Dreyer Scott | EVP, Chief Commercial Officer | S - Sale | $30.00 | -2,255 | 124,421 | -2% | -$67,661 | ||||||
| D | 2025-03-17 | AKRO | Akero Therapeutics, Inc. | Yale Catriona | Chief Development Officer | S - Sale+OE | $44.76 | -10,000 | 95,034 | -10% | -$447,605 | |||||
| M | 2025-03-14 | PTCT | Ptc Therapeutics, Inc. | Pauwels Eric | CHIEF BUSINESS OFFICER | S - Sale | $56.16 | -11,220 | 72,640 | -13% | -$630,104 | |||||
| M | 2025-03-14 | MIRM | Mirum Pharmaceuticals, Inc. | Heron Patrick J | Dir | P - Purchase | $44.11 | +549 | 3,735,584 | 0% | +$24,214 | |||||
2025-03-14 | ABBV | Abbvie Inc. | Reents Scott T | EVP, CFO | S - Sale | $212.34 | -17,644 | 11,577 | -60% | -$3,746,527 | ||||||
2025-03-17 | ZOM | Zomedica Corp. | Rowe Jeffrey M | Dir | P - Purchase | $0.07 | +1,439,005 | 13,679,485 | +12% | +$96,098 | ||||||
2025-03-14 | BGNE | Beigene, Ltd. | Wu Xiaobin | Pres, COO, GM China | S - Sale | $0.00 | -0 | 1,191,575 | 0% | -$0 | ||||||
2025-03-17 | ZOM | Zomedica Corp. | Macleod Christopher Ross | Dir | P - Purchase | $0.06 | +143,000 | 143,000 | New | +$8,437 | ||||||
2025-03-17 | ZOM | Zomedica Corp. | Powers Johnny D | Dir | P - Purchase | $0.07 | +500,000 | 5,700,000 | +10% | +$33,650 | ||||||
2025-03-17 | ZOM | Zomedica Corp. | Heaton Larry C II | CEO | P - Purchase | $0.06 | +500,000 | 1,000,000 | +100% | +$29,702 | ||||||
2025-03-17 | ZOM | Zomedica Corp. | Blair Anthony K | COO | P - Purchase | $0.06 | +500,000 | 900,000 | +125% | +$30,000 | ||||||
2025-03-17 | ZOM | Zomedica Corp. | Klass Russell Kevin | SVP of Sales | P - Purchase | $0.07 | +699,980 | 3,200,030 | +28% | +$48,999 | ||||||
| D | 2025-03-18 | CYTK | Cytokinetics Inc | Malik Fady Ibraham | EVP Research, Development | S - Sale+OE | $43.58 | -2,000 | 140,455 | -1% | -$87,160 | |||||
| M | 2025-03-14 | PRLD | Prelude Therapeutics Inc | Vaddi Krishna | CEO | P - Purchase | $0.75 | +39,105 | 2,973,638 | +1% | +$29,460 | |||||
2025-03-17 | ZOM | Zomedica Corp. | Williams Rodney James | Dir | P - Purchase | $0.07 | +100,000 | 140,000 | +250% | +$6,900 | ||||||
2025-03-17 | ALT | Altimmune, Inc. | Sohn Catherine A. | Dir | P - Purchase | $5.78 | +1,000 | 1,000 | New | +$5,785 | ||||||
2025-03-17 | APLS | Apellis Pharmaceuticals, Inc. | Chopas James George | VP, Chief Accounting Officer | S - Sale | $24.82 | -183 | 47,955 | 0% | -$4,543 | ||||||
2025-03-13 | MLYS | Mineralys Therapeutics, Inc. | Samsara Biocapital Gp, LLC | 10% | P - Purchase | $13.50 | +600,000 | 5,674,916 | +12% | +$8,100,000 | ||||||
2025-03-13 | MLYS | Mineralys Therapeutics, Inc. | Akkaraju Srinivas | Dir | P - Purchase | $13.50 | +600,000 | 5,674,916 | +12% | +$8,100,000 | ||||||
2025-03-17 | CYTK | Cytokinetics Inc | Callos Andrew | EVP, Chief Commercial Officer | S - Sale | $44.38 | -2,775 | 34,888 | -7% | -$123,155 | ||||||
2025-03-17 | CYTK | Cytokinetics Inc | Malik Fady Ibraham | EVP Research, Development | S - Sale | $44.38 | -4,389 | 101,005 | -4% | -$194,784 | ||||||
2025-03-17 | CYTK | Cytokinetics Inc | Blum Robert I | Pres, CEO | S - Sale | $44.38 | -12,648 | 330,699 | -4% | -$561,318 | ||||||
2025-03-13 | MLYS | Mineralys Therapeutics, Inc. | Ra Capital Management, L.P. | Dir | P - Purchase | $13.50 | +1,296,296 | 6,147,280 | +27% | +$17,499,996 | ||||||
2025-03-13 | ARWR | Arrowhead Pharmaceuticals, Inc. | Anzalone Christopher Richard | CEO | S - Sale | $15.07 | -51,425 | 4,062,377 | -1% | -$774,975 | ||||||
2025-03-17 | OPK | Opko Health, Inc. | Frost Phillip Md Et Al | CEO, COB, 10% | P - Purchase | $1.74 | +200,000 | 247,197,576 | 0% | +$347,820 | ||||||
2025-03-13 | PTCT | Ptc Therapeutics, Inc. | Okey Stephanie | Dir | S - Sale | $54.00 | -5,000 | 8,867 | -36% | -$270,000 | ||||||
2025-03-13 | NGNE | Neurogene Inc. | Cvijic Christine Mikail | Pres, CFO | S - Sale | $16.94 | -4,501 | 72,343 | -6% | -$76,247 | ||||||
2025-03-14 | RAPP | Rapport Therapeutics, Inc. | Bredt David | Chief Scientific Officer | S - Sale | $10.85 | -8,500 | 469,142 | -2% | -$92,205 | ||||||
| DM | 2025-03-13 | ARQT | Arcutis Biotherapeutics, Inc. | Burnett Patrick | See Remarks | S - Sale+OE | $14.99 | -61,403 | 121,936 | -33% | -$920,510 | |||||
2025-03-14 | AMRX | Amneal Pharmaceuticals, Inc. | Patel Tushar Bhikhubhai | 10% | S - Sale | $8.35 | -5,000,000 | 48,578,209 | -9% | -$41,750,000 | ||||||
2025-03-17 | CYTK | Cytokinetics Inc | Blum Robert I | Pres, CEO | S - Sale | $44.65 | -25,000 | 343,347 | -7% | -$1,116,250 | ||||||
| D | 2025-03-17 | CYTK | Cytokinetics Inc | Callos Andrew | EVP, Chief Commercial Officer | S - Sale+OE | $45.14 | -20,900 | 37,663 | -36% | -$943,426 | |||||
2025-03-13 | PHAT | Phathom Pharmaceuticals, Inc. | Parikh Asit | Dir | P - Purchase | $4.42 | +10,000 | 85,500 | +13% | +$44,200 | ||||||
2025-03-05 | BPMC | Blueprint Medicines Corp | Albers Jeffrey W. | Dir | S - Sale | $88.80 | -5,766 | 146,630 | -4% | -$512,021 | ||||||
2025-03-13 | VRTX | Vertex Pharmaceuticals Inc / Ma | Altshuler David | EVP, Chief Scientific Officer | S - Sale | $510.00 | -3,231 | 23,281 | -12% | -$1,647,810 | ||||||
| M | 2025-03-13 | GYRE | Gyre Therapeutics, Inc. | Ma Songjiang | Pres | S - Sale | $12.06 | -4,000 | 2,831,260 | 0% | -$48,220 | |||||
2025-03-12 | AKRO | Akero Therapeutics, Inc. | Cheng Andrew | Pres, CEO | S - Sale | $44.88 | -1,738 | 654,324 | 0% | -$78,001 | ||||||
| D | 2025-03-14 | CYTK | Cytokinetics Inc | Callos Andrew | EVP, Chief Commercial Officer | S - Sale+OE | $45.00 | -100 | 37,663 | 0% | -$4,500 | |||||
2025-03-12 | AKRO | Akero Therapeutics, Inc. | Young Jonathan | COO | S - Sale | $44.88 | -607 | 260,540 | 0% | -$27,242 | ||||||
2025-03-12 | AKRO | Akero Therapeutics, Inc. | Yale Catriona | Chief Development Officer | S - Sale | $44.88 | -614 | 95,034 | -1% | -$27,556 | ||||||
2025-03-12 | AKRO | Akero Therapeutics, Inc. | White William Richard | CFO | S - Sale | $44.88 | -676 | 61,959 | -1% | -$30,339 | ||||||
2025-03-12 | AKRO | Akero Therapeutics, Inc. | Rolph Timothy | Chief Scientific Officer | S - Sale | $44.88 | -516 | 169,721 | 0% | -$23,158 | ||||||
2025-03-14 | ETST | Earth Science Tech, Inc. | Sanchez Yovan Arturo | Dir | P - Purchase | $0.12 | +100,000 | 1,606,151 | +7% | +$12,000 | ||||||
| D | 2025-03-13 | PTGX | Protagonist Therapeutics, Inc | Molina Arturo Md | Chief Medical Officer | S - Sale+OE | $55.74 | -30,514 | 83,892 | -27% | -$1,700,850 | |||||
| D | 2025-03-12 | PTGX | Protagonist Therapeutics, Inc | Ali Asif | CFO | S - Sale+OE | $58.73 | -24,903 | 62,821 | -28% | -$1,462,553 | |||||
2025-03-12 | EOLS | Evolus, Inc. | Parschauer Karah Herdman | Dir | S - Sale | $12.99 | -12,888 | 32,183 | -29% | -$167,465 | ||||||
2025-03-12 | ALZN | Alzamend Neuro, Inc. | Ault Milton C III | Dir, 10% | P - Purchase | $0.68 | +100 | 194,222 | 0% | +$68 | ||||||
2025-03-13 | ANIP | Ani Pharmaceuticals Inc | Cook Meredith | SVP, GC, SEC. | S - Sale | $63.33 | -400 | 80,545 | 0% | -$25,332 | ||||||
| D | 2025-03-12 | PTCT | Ptc Therapeutics, Inc. | Boulding Mark Elliott | EVP, CLO | S - Sale+OE | $53.30 | -15,521 | 103,901 | -13% | -$827,233 | |||||
| D | 2025-03-12 | KNSA | Kiniksa Pharmaceuticals International, Plc | Megna Michael R | CHIEF ACCOUNTING OFFICER | S - Sale+OE | $22.45 | -9,051 | 26,528 | -25% | -$203,195 | |||||
| D | 2025-03-12 | KNSA | Kiniksa Pharmaceuticals International, Plc | Ragosa Mark | CFO | S - Sale+OE | $22.25 | -36,372 | 22,958 | -61% | -$809,277 | |||||
| D | 2025-03-12 | BPMC | Blueprint Medicines Corp | Albers Jeffrey W. | Dir | S - Sale+OE | $87.80 | -7,500 | 152,396 | -5% | -$658,500 | |||||
2025-03-12 | RPTX | Repare Therapeutics Inc. | Koehler Maria | EVP, CHIEF MEDICAL OFFICER | S - Sale | $1.14 | -3,596 | 227,813 | -2% | -$4,099 | ||||||
2025-03-12 | RPTX | Repare Therapeutics Inc. | Zinda Michael | EVP, CHIEF SCIENTIFIC OFFICER | S - Sale | $1.14 | -5,611 | 80,297 | -7% | -$6,397 | ||||||
2025-03-12 | RPTX | Repare Therapeutics Inc. | Forte Steve | EVP, CFO | S - Sale | $1.14 | -6,884 | 54,786 | -11% | -$7,848 | ||||||
2025-03-12 | RPTX | Repare Therapeutics Inc. | Segal Lloyd Mitchell | Pres, CEO | S - Sale | $1.14 | -21,179 | 231,952 | -8% | -$24,144 | ||||||
| DM | 2025-03-12 | MDGL | Madrigal Pharmaceuticals, Inc. | Craves Fred B | Dir | S - Sale+OE | $328.54 | -15,470 | 383,547 | -4% | -$5,082,480 | |||||
| M | 2025-03-12 | PRLD | Prelude Therapeutics Inc | Vaddi Krishna | CEO | P - Purchase | $0.71 | +97,500 | 2,934,533 | +3% | +$69,564 | |||||
2025-03-13 | ALT | Altimmune, Inc. | Weaver Gregory L | CFO | P - Purchase | $5.20 | +10,000 | 10,000 | New | +$51,996 | ||||||
| DM | 2025-03-07 | VREO | Vireo Growth Inc. | Chicago Atlantic Credit Opportunities, LLC | 10% | P - Purchase | $0.62 | +32,222,500 | 110,553,183 | +41% | +$20,084,466 | |||||
2025-03-12 | VRNA | Verona Pharma Plc | Rickard Kathleen A. | Chief Medical Officer | S - Sale | $8.35 | -79,264 | 2,608,976 | -3% | -$661,942 | ||||||
| D | 2025-03-12 | SRPT | Sarepta Therapeutics, Inc. | Nicaise Claude | Dir | S - Sale+OE | $99.64 | -2,491 | 27,812 | -8% | -$248,203 | |||||
| M | 2025-03-11 | ZYME | Zymeworks Inc. | Ecor1 Capital, LLC | Dir, 10% | P - Purchase | $12.13 | +1,081,980 | 16,802,141 | +7% | +$13,120,914 | |||||
2025-03-11 | TSVT | 2Seventy Bio, Inc. | Kynam Global Healthcare Master Fund, LP | 10% | S - Sale | $4.93 | -16,238,047 | 0 | -100% | -$80,053,572 | ||||||
| M | 2025-03-12 | RAPP | Rapport Therapeutics, Inc. | Ignelzi Troy A. | CFO | P - Purchase | $10.10 | +10,000 | 10,000 | New | +$100,988 | |||||
2025-03-12 | RAPP | Rapport Therapeutics, Inc. | Young Wendy B. | Dir | P - Purchase | $10.21 | +6,000 | 6,000 | New | +$61,250 | ||||||
2025-03-06 | COLL | Collegium Pharmaceutical, Inc | Dreyer Scott | EVP, Chief Commercial Officer | S - Sale | $30.00 | -15,387 | 126,676 | -11% | -$461,672 | ||||||
2025-03-11 | COLL | Collegium Pharmaceutical, Inc | Tupper Colleen | EVP, CFO | S - Sale | $30.01 | -10,445 | 165,246 | -6% | -$313,413 | ||||||
2025-03-11 | IONS | Ionis Pharmaceuticals Inc | Monia Brett P | CEO | S - Sale | $32.32 | -140 | 180,980 | 0% | -$4,525 | ||||||
2025-03-13 | CYTK | Cytokinetics Inc | Callos Andrew | EVP, Chief Commercial Officer | S - Sale | $43.62 | -26,771 | 37,663 | -42% | -$1,167,751 | ||||||
2025-03-13 | LLY | Eli Lilly & Co | Zakrowski Donald A | SVP, Finance, CAO | S - Sale | $818.24 | -1,000 | 7,560 | -12% | -$818,240 | ||||||
2025-03-13 | DYN | Dyne Therapeutics, Inc. | Friedl-Naderer Johanna | Chief Commercial Officer | S - Sale | $12.12 | -143 | 96,057 | 0% | -$1,733 | ||||||
2025-03-11 | DYN | Dyne Therapeutics, Inc. | Scalzo Richard William | SVP, Head of Finance, Admin. | S - Sale | $11.38 | -1,343 | 122,330 | -1% | -$15,283 | ||||||
2025-03-11 | DYN | Dyne Therapeutics, Inc. | Beskrovnaya Oxana | Chief Scientific Officer | S - Sale | $11.38 | -2,153 | 195,840 | -1% | -$24,501 | ||||||
| M | 2025-03-11 | GYRE | Gyre Therapeutics, Inc. | Ma Songjiang | Pres | S - Sale | $11.57 | -4,000 | 2,835,260 | 0% | -$46,280 | |||||
2025-01-10 | CLRB | Cellectar Biosciences, Inc. | Longcor Jarrod | COO | P - Purchase | $0.28 | +30,000 | 83,141 | +56% | +$8,400 | ||||||
| M | 2025-03-10 | IRON | Disc Medicine, Inc. | Ashiya Mona | Dir | S - Sale | $54.31 | -312,384 | 194,209 | -62% | -$16,965,596 | |||||
| M | 2025-03-10 | IRON | Disc Medicine, Inc. | Orbimed Advisors LLC | Dir | S - Sale | $54.31 | -312,384 | 194,209 | -62% | -$16,965,596 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |